Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2009

Hofmann Uta B, Kauczok-Vetter Claudia S, Houben Roland, Becker Jürgen C

Abstract excerpt

PURPOSE: Recently, gene amplification and overexpression of KIT as well as activating mutations in the KIT gene have been described to occur in certain subsets of melanoma. These findings suggest KIT as a potential target for therapy with imatinib mesylate in these melanomas. To date, data on the KIT status in uveal melanoma (UM) is limited. EXPERIMENTAL DESIGN: We analyzed the expression of the KIT protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Stem Cell Factor

Share to Uveal Neoplasms

Source

Identifiers

PMID: 19118061
DOI: 10.1158/1078-0432.CCR-08-2243

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.PMID 19118061Read ↗

Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.Semantic proximity Read ↗

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.Semantic proximity Read ↗

Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.Semantic proximity Read ↗

Analysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma.Semantic proximity Read ↗

C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions.Semantic proximity Read ↗

Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays.Semantic proximity Read ↗

Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis.Semantic proximity Read ↗

Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications.Semantic proximity Read ↗

Major response to imatinib mesylate in KIT-mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.